期刊文献+

慢性进行性眼外肌麻痹发病机制探讨 被引量:1

A STUDY OF PATHOGENESIS ON CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA
下载PDF
导出
摘要 ①目的 探讨慢性进行性眼外肌麻痹 (CPEO)发病的分子机制。②方法 采用聚合酶链反应 (PCR)、PCR 限制性片段长度多态性 (PCR RFLP)技术以及PCR 单链构象多态性 (PCR SSCP)技术 ,对 4例CPEO病人和 10例非CPEO病人受累眼外肌线粒体DNA(mtDNA)的 84 83~ 1345 9碱基部位的缺失突变、tRNA(Leu)基因A32 4 3G位点的点突变以及tRNA(Leu)基因其他位点的突变情况进行检测分析。③结果 在 1例CPEO病人眼外肌标本中检测到mtDNA的 84 83~ 1345 9碱基部位的缺失突变 ;未检测出A32 4 3G点突变及mtDNAtRNA(Leu)基因的其他点突变。④结论 mtDNA的 84 83~ 1345 9碱基部位缺失突变可能与CPEO的发病有关。 Objective\ To study mitochondrial DNA(mtDNA) mutations in chronic progressive external ophthalmoplegia(CPEO) and explore the genetic pathogenesis of the disease.\ Methods\ The mtDNA deletion mutation, tRNA(Leu) gene A3243G point mutation and other point mutations in tRNA(Leu) gene in the affected extra ocular muscles of 4 CPEO patients and 10 ocular disease (except CPEO) patients were detected by polymerase chain reaction(PCR), PCR combined with restricted fragment length polymorphism(PCR RFLP) and PCR combined single strand conformation polymorphism(PCR SSCP), respectively. Results\ The mtDNA deletion mutation was found in one CPEO patients extra ocular muscle. The tRNA(Leu) gene A3243G point mutation and other point mutations in tRNA(Leu) gene were not found in all the patients with or without CPEO. \ Conclusion\ The deletion mutation of mitochondrial DNA might be related to the pathogenesis of CPEO.
作者 滕蕾 孔庆兰
出处 《青岛大学医学院学报》 CAS 2003年第3期281-283,286,共4页 Acta Academiae Medicinae Qingdao Universitatis
关键词 慢性进行性眼外肌麻痹 发病机制 分子机制 聚合酶链反应 眼外肌线粒体DNA ophthalmoplegia, chronic progressive external DNA , mitochondrion point mutation polymerase chain reaction
  • 相关文献

同被引文献13

  • 1张平,张申宁,陈光辉.慢性进行性眼外肌麻痹2例报道及文献复习[J].临床与实验病理学杂志,2004,20(6):692-694. 被引量:3
  • 2王岩,徐丽,刘驰,庄晓彤.慢性进行性眼外肌麻痹1例[J].眼科新进展,2006,26(5):366-366. 被引量:1
  • 3Schon, E.A., Rizzuto, R., Moraes, C. T., et al. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA[J]. Science, 1989, 244 (4902): 346.
  • 4Anderson, S., Bankier, A.T., Barrell, B.G., et al. Sequence and organization of the human mitochondrial genome[J]. Nature, 1981, 290 (5806): 457-465.
  • 5Wallace, D.C., Lott, M.T., Brnwn, M.D., et al. Mitoehondria and neuro-ophthalmologic diseases[J]. The metabolic and molecular basis of inherited disease, 2001: 2425-2509.
  • 6Holt, I.J., Harding, A.E. and Morgan-Hughes, J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies [J]. Nature, 1988, 331 (6158):717-719.
  • 7Couher-Mackie, M.B., Applegarth, D.A., Toone, J.R., et al. A protocol for detection of mitochondrial DNA deletions: characterization of a novel deletion[J]. Clin Biochem, 1998, 31 (8) : 627-632.
  • 8Kawai, H., Akaike, M., Yokoi, K., et al. Mitochondrial encephalomyopathy with autosomal dominant inheritance: a clinical and genetic entity of mitochondrial diseases[J]. Muscle Nerve, 1995, 18 (7): 753- 760.
  • 9McDonald, D.G., McMenamin, J.B., Farrell, M.A., et al. Familial childhood onset neuropathy and cirrhosis with the 4977bp mitochondrial DNA deletion[J]. Am J Med Genet, 2002, 111 (2): 191-194.
  • 10Carta, A., D'Adda, T., Carrara, F., et al. Uhrastructural analysis of extraoeular muscle in chronic progressive external ophthalmoplegia[J]. Arch Ophthalmol, 2000, 118 (10): 1441-1445.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部